News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Medivir (MVRBF) Initiates Clinical Study Of Birinapant In Combination With KEYTRUDA (Pembrolizumab) In Patients With Treatment-Refractory Solid Tumours 8/18/2017
Immunicum Completes Strategic Analysis And Defines Updated Clinical Development Plan For Ilixadencel 8/17/2017
Biogen (BIIB) Gained $1 Billion Overnight After Becoming Goldman Sachs' Favorite Biotech 8/17/2017
Tempus Selected As Sequencing And Analytics Provider By The Prostate Cancer Clinical Trials Consortium For Phase II Clinical Trial 8/17/2017
PolyPid Ltd. Completes Enrollment In Phase Ib/II Study Of D-PLEX In Post-Cardiac Surgery Sternal Infection 8/16/2017
ARCA biopharma Announces Completion Of Enrollment For GENETIC-AF Phase IIb Clinical Trial 8/16/2017
Iovance Biotherapeutics Announces First Patient Dosed In C-145-04 Phase II Trial In Cervical Cancer 8/16/2017
Mateon Therapeutics (MATN) Announces Results From Second Interim Analysis Of CA4P Phase II/III FOCUS Study In Platinum-Resistant Ovarian Cancer 8/16/2017
Opthea Presents Additional Positive Data From OPT-302 Phase I/IIa Wet AMD Trial At ASRS Meeting 8/16/2017
Dimerix Limited To Present Analysis Of DMX-200 Phase IIa Clinical Trial In Chronic Kidney Disease At The American Society of Nephrology (ASN) Annual Kidney Week 2017 8/16/2017
New ThromboGenics NV (TBGNF)' Ocriplasmin Clinical And Health Economic Data Presented At ASRS 2017 Annual Scientific Meeting In Boston 8/16/2017
Abeona Therapeutics Announces Pivotal Expansion Of ABO-102 Gene Therapy Clinical Trials In Sanfilippo Syndrome Type A 8/16/2017
U.S. FDA Grants Lion TCR Two Orphan Drug Designations Of T Cell Therapy Against Hepatocellular Carcinoma 8/16/2017
Omeros (OMER) Data Show Continued Improvement In Patients With IgA Nephropathy Treated With OMS721 8/15/2017
CymaBay Therapeutics Announces The Publication Of The Seladelpar Proof-Of-Concept Study For Primary Biliary Cholangitis In Lancet Gastroenterology And Hepatology 8/15/2017
Conatus Pharma Announces Completion Of Enrollment In ENCORE-NF Phase IIb Clinical Trial Of Emricasan In Patients With NASH Fibrosis 8/15/2017
Galapagos (GLPG.BR)' Phase II Results With GLPG1690 are 'Extremely Exciting' 8/14/2017
Inventiva Release: Odiparcil Awarded Orphan Drug Designation For The Treatment Of MPS VI By The FDA 8/14/2017
Kalytera Submits Phase II Study Protocol To Irbs For Cannabidiol In The Prevention Of Graft Versus Host Disease 8/14/2017
SCYNEXIS, Inc. (SCYX) Presents New Data Supporting Oral SCY-078 For The Clinical Treatment Of Vulvovaginal Candidiasis Infections At The 2017 IDSOG Annual Meeting 8/14/2017
Zynerba (ZYNE) Sinks As Osteoarthritis Med Flunks Mid-Stage Trial 8/14/2017
Oncoceutics Release: ONC201 Trial For Neuroendocrine Cancer Begins At Cleveland Clinic 8/14/2017
Phase IIb Results Of Viamet’s Oral VT-1161 For The Treatment Of Recurrent Vulvovaginal Candidiasis Presented At IDSOG Annual Meeting 8/11/2017
Bonti Announces Topline Results Of EB-001 Phase IIA Clinical Study In Glabellar Lines 8/10/2017
Anthera Announces FDA Orphan Drug Designation For Blisibimod For The Treatment Of IgA Nephropathy 8/10/2017
TG Therapeutics (TGTX) Announces Successful Outcome From The First Pre-Planned Interim Analysis By Independent DSMB Of The DLBCL Cohort In The UNITY-NHL Phase IIb Trial 8/10/2017
ARCA biopharma Announces Genetic-Af Data And Safety Monitoring Board Recommendation To Complete Phase IIb Genetic-Af Clinical Trial Based On Efficacy And Safety Data In Phase IIb Interim Analysis 8/10/2017
ARCA biopharma Announces GENETIC-AF Data And Safety Monitoring Board Recommendation To Complete Phase 2B GENETIC-AF Clinical Trial Based On Efficacy And Safety Data In Phase IIB Interim Analysis 8/10/2017
Achillion (ACHN) Shares Surge on Promising ACH-4471 Phase II Data 8/9/2017
Allegro Ophthalmics LLC Announces Positive Topline Results From DEL MAR Phase IIb Stage 2 Trial Evaluating Luminate In Patients With Diabetic Macular Edema 8/9/2017
Can-Fite BioPharma (CFBI) Completes Patient Enrolment For Its Phase II Study Of Namodenoson In The Treatment Of Liver Cancer 8/9/2017
Mologen (MOLGF.PK): Results Of The Extension Phase Of The Exploratory Phase Ib/Iia Study In HIV 8/9/2017
BioSight Completed Patient Enrollment And Treatment In Its Extended Acute Leukemia Phase I/II Clinical Trial With BST-236, A Novel Cytarabine Pro-Drug 8/9/2017
Mithra Pharmaceuticals Release: Recruitment Completed In Estelle Population Pk Substudy 8/9/2017
EndoLogic Announces Feedback From Positive FDA Meeting For Renzapride In Diabetic Gastroparesis 8/9/2017
CytoDyn (CYDY) Provides Update On Enrollment In Its Pivotal Phase Ib/III HIV Combination Trial 8/9/2017
MyoKardia Shares Surge on Positive Phase II Results for Heart Muscle Disease 8/8/2017
Esperion (ESPR) Stock Gains On Strong Phase II Data 8/8/2017
FibroGen (FGEN) Announces Positive Topline Results From Phase II Study Of Pamrevlumab In Idiopathic Pulmonary Fibrosis 8/8/2017
FDA Awards Orphan Status To Brain Cancer Vaccine Developed At Roswell Park Cancer Institute 8/8/2017
TapImmune (TPIV) Amends Phase II Clinical Trial To Focus On Larger Population Of Women With Platinum-Sensitive Ovarian Cancer With Greatest Unmet Need For New Treatments 8/8/2017
Zynerba (ZYNE)’s Failed Cannabidiol Gel Trial Has Upside for Rival GW Pharma (GWPH) 8/8/2017
Amylyx Doses First Patient In Phase II Clinical Trial Of AMX0035 For The Treatment Of Amyotrophic Lateral Sclerosis 8/8/2017
Verona Pharma (VRP.L) Interim Results For The Six Months Ended June 30, 2017 And Clinical Development Update 8/8/2017
Kura Oncology Reports Second Quarter 2017 Financial Results And Provides Update On Tipifarnib Phase II Study 8/8/2017
Gemphire Shares Drop on Disappointing Phase II Results for LDL Drug 8/7/2017
Biohaven (BHVN) Completes Randomization In Phase II/III Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 8/7/2017
Jaguar Health Subsidiary Napo Pharmaceuticals, Inc. Receives Orphan-Drug Designation For Mytesi (Crofelemer) For Treatment Of Short Bowel Syndrome 8/7/2017
FDA Grants Orphan Drug Designation To Kadmon’s Tesevatinib For The Treatment Of EGFR-Mutated Non-Small Cell Lung Cancer 8/7/2017
Zynerba (ZYNE)'s ZYN002 Flunks Phase II Epilepsy Study 8/7/2017
Innovation Pharma (Formerly known as Cellceutix) (CTIX) Completes Patient Enrollment In Phase II Study Of Brilacidin For The Prevention Of Severe Oral Mucositis 8/7/2017
Cyclacel Pharma (CYCC) Announces Selection Of Recommended Phase II Dose For CYC065 And Evidence Of Durable Target Engagement And Mcl-1 Biomarker Suppression 8/7/2017
AIT Therapeutics Announces Enrollment Of First Patient Into Its NO-NTM Abscessus Phase II Trial In Nontuberculous Mycobacteria (NTM) 8/7/2017
Calithera Biosciences (CALA) Initiates A Randomized Phase II Combination Trial Of CB-839 In Patients With Renal Cell Carcinoma 8/7/2017
SCYNEXIS, Inc. (SCYX) Announces Initiation of Dosing in Phase II Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis 8/4/2017
Avelas Biosciences Doses First Patient In Phase II Study Of AVB-620 In Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery 8/4/2017
Theravance Biopharma (TBPH) Announces Positive Top-Line Results From Phase IIb Study Of Velusetrag (TD-5108) In Patients With Gastroparesis 8/3/2017
Enzychem Lifesciences, Corp's Investigational New Drug Application (IND) For Chemoradiation Induced Oral Mucositis Had Been Granted By The FDA 8/3/2017
BioMarin (BMRN) Announces Plans To Progress Both The 6e13vg/Kg And 4e13 Vg/Kg Doses Of BMN 270, Its Investigational Gene Therapy For Hemophilia A, Into Phase III Studies 8/3/2017
Oxeia Announces Clinical Advancement Of Concussion Treatment 8/3/2017
Spark Therapeutics (ONCE) Unveils Encouraging Hemophilia A Data 8/3/2017
Roche (RHHBY)’s Tecentriq Hits Trouble with NICE in Bladder Cancer 8/3/2017
Earth Science Tech, Inc. Signs Contract With Absolu To Advance Phase-II Rollout On MSN-2 Medical Device 8/3/2017
Bellerophon Therapeutics (BLPH) Announces FDA Agreement On Phase IIb Study Design For INOpulse In Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) 8/3/2017
Asterias Biotherapeutics Opens Two Additional Clinical Sites For AST-OPC1 SCiStar Study 8/3/2017
Treatment With Qu Biologics’ Novel Immune Therapy For Ulcerative Colitis Results In High Clinical And Endoscopic Response Rates And Histological Improvement 8/3/2017
Avelas Biosciences Doses First Patient In Phase II Study Of AVB-620 In Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery 8/3/2017
Geron (GERN) Under Pressure as Clinical Trial Changes Causes Delays 8/2/2017
Antibe Therapeutics (ATE.V) Receives Approval To Initiate Phase II Gastrointestinal Endoscopy Clinical Trial 8/2/2017
IRX Therapeutics To Present IRX-2 Clinical And Biomarker Updates At Upcoming Medical Conferences 8/2/2017
Aprea Announces First Patient Enrolled In Phase Ib/II Clinical Study Of APR-246 For The Treatment Of Platinum-Resistant High-Grade Serous Ovarian Cancer 8/2/2017
Biocryst (BCRX) Announces Initiation Of ZENITH-1, A Clinical Trial To Evaluate BCX7353 As An Acute Treatment Of Hereditary Angioedema Attacks 8/2/2017
Karolinska Development AB Aprea Announces First Patient Enrolled In Phase Ib/II Clinical Study 8/2/2017
Aclaris (ACRS) Submits Investigational New Drug Application For ATI-50002 To Treat Alopecia Areata 8/2/2017
Cytokinetics (CYTK) Announces Positive Results From Phase II Clinical Trial Of Omecamtiv Mecarbil In Japanese Patients With Heart Failure 8/2/2017
Benitec (BLT.AX) Regroups under Partnership with Patrick Soon-Shiong 8/2/2017
CTI BioPharma Announces First Patient Enrolled In Phase II Trial Of Pacritinib In Patients With Myelofibrosis Who Have Thrombocytopenia And Who Have Been Previously Treated With Ruxolitinib 8/1/2017
Flex Pharma (FLKS) Initiates ALS Phase II Trial With FLX-787 In U.S. 8/1/2017
AstraZeneca PLC (AZN) Release: Acalabrutinib Granted Breakthrough Therapy Designation By U.S. FDA For The Treatment Of Patients With Mantle Cell Lymphoma 8/1/2017
Acceleron Pharma Announces First Patient Treated In Phase II Clinical Trial Of ACE-083 In Charcot-Marie-Tooth Disease 8/1/2017
Aptinyx Initiates Phase II Clinical Studies Evaluating NYX-2925 In Two Chronic Pain Conditions 8/1/2017
CTI BioPharma Announces First Patient Enrolled In Phase II Trial Of Pacritinib In Patients With Myelofibrosis Who Have Thrombocytopenia And Who Have Been Previously Treated With Ruxolitinib 8/1/2017
EyeGate Pharma Pharma Enrolls First Patient In Phase IIb Clinical Study Of EGP-437 For Cataract Surgery 8/1/2017
Mateon Therapeutics (MATN) Completes Enrollment In Phase II Portion Of FOCUS Study Of CA4P For Platinum-Resistant Ovarian Cancer 8/1/2017
Madrigal Completes Enrollment In Phase II Proof-Of-Concept Study With MGL-3196 For Treatment Of NASH 8/1/2017
Protalex (PRTX) Completes Data Analysis Of Second Dose Cohort Of U.S. Phase I/II Study Of PRTX-100 In ITP 8/1/2017
Proteostasis (PTI) Announces Progression Of PTI-428 And PTI-801 To Longer Duration Studies In CF Subjects 8/1/2017
Ra Pharma (RARX) Receives Orphan Drug Designation From The U.S. FDA For RA101495 For The Treatment Of Paroxysmal Nocturnal Hemoglobinuria 7/31/2017
PellePharm, Inc Announces Topline Results From Phase II Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing 7/31/2017
Intercept Pharma (ICPT) Announces Positive Results From The Phase II AESOP Trial Evaluating OCA For The Treatment Of Patients With Primary Sclerosing Cholangitis 7/31/2017
Galera Announces Promising Innovative Medicines Designation From The United Kingdom’s Medicines And Healthcare Products Regulatory Agency For GC4419 For The Reduction Of Oral Mucositis In Head And Neck Cancer Patients 7/31/2017
American Journal Of Psychiatry Publishes Minerva Neurosciences (NERV)’ MIN-101 Phase IIb Trial Results For Treatment Of Negative Symptoms In Schizophrenia 7/31/2017
Glenmark Pharma Reports Positive Data In A Phase IIa Study Of GBR 830 For The Treatment Of Patients With Atopic Dermatitis 7/31/2017
TRANSGENE (ENX:TNG) Release: First Patient Dosed In A Phase 1/2 Trial Of Pexa-Vec + Opdivo For The First-Line Treatment Of Advanced Liver Cancer 7/31/2017
Tiziana Life Sciences Plc Release: Publication Of Research Article On Foralumab, A Fully Human Anti-Cd3 Antibody Being Developed As An Oral Therapy For Nash And Autoimmune Diseases 7/28/2017
Pluristem Therapeutics (PSTI) Release: New Data From ARS Study Shows Significant Hematological Deficiencies Even At Low Radiation Levels; PLX-R18 Supports Hematological Recovery 7/28/2017
Amgen (AMGN) Falls After Earnings Update Reveals Embarassingly 'Bare' Pipeline 7/27/2017
Cytokinetics (CYTK) Announces Start Of FORTITUDE-ALS, A Phase II Clinical Trial Of CK-2127107 In Patients With Amyotrophic Lateral Sclerosis 7/27/2017
Chikungunya-Fever: Themis Starts Phase II Clinical Study In Endemic Area 7/27/2017
European Commission (EC) Grants Orphan Drug Designation To Allena Pharma’ Investigational Therapy For The Treatment Of Primary Hyperoxaluria 7/27/2017
TrovaGene (TROV) Announces FDA Approval Of IND For Phase Ib/II Trial Of PCM-075 In Patients With Acute Myeloid Leukemia 7/27/2017
Quark Pharmaceuticals Inc. Reports Positive Results From A Phase II Study To Evaluate The Efficacy And Safety Of QPI-1002 For The Prevention Of Acute Kidney Injury (AKI) In Subjects At High Risk Of AKI Following Cardiac Surgery 7/27/2017
Eiger Biopharma Announces FDA Fast Track Designation Granted For Pegylated Interferon Lambda In Hepatitis Delta Virus Infection 7/27/2017
AMO Pharma Receives FDA Orphan Drug Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy 7/27/2017
Medical Marijuana, Inc. Major Investment Axim Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome 7/27/2017
BioPharmX Release: Summer AAD Panel To Discuss BPX-01 For Acne And Rosacea 7/27/2017
Esperion (ESPR) Announces Initiation Of Phase II Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor 7/27/2017
Eli Lilly (LLY) Shakes Up Cancer R&D Strategy, Seeks New Home for Seven Pipeline Drugs 7/26/2017
2 Tiny Cancer Biotechs That Could Gain Steam by Year-End 7/26/2017
BioTime (BTX) Receives DSMB Approval To Start Third Patient Cohort In Clinical Trial For Dry-AMD; Commences Patient Enrollment In The U.S. 7/26/2017
Complexa Raises $62 Million In Series C Financing To Test CXA-10 In Two Orphan Disease Proof-Of-Concept Trials 7/26/2017
Oncolytics Biotech (ONC.TO) To Present REOLYSIN Safety Data In Combination With Chemotherapy At ESMO 2017 Congress 7/26/2017
First Patient Enrolled In Oncoquest's Phase I/II Study Combining Oregovomab With Hiltonol In Recurrent Ovarian Cancer 7/26/2017
Novavax (NVAX) Plunges Some More Afer New Mid-Stage RSV Data Fails to Impress 7/26/2017
Verona Pharma (VRP.L) Doses First Patients In Phase IIb Clinical Trial Of RPL554 For COPD Maintenance Treatment 7/26/2017
Pharming Group (PHGUF.PK) Announces Publication Of RUCONEST Prophylactic Data In Lancet 7/26/2017
BioPharm Executive: And So It Continues: Let's Get Rid of Clinical Trials (Part 2) 7/26/2017
5 Biotechs With $45 Billion Worth of Not-Yet Approved Drugs in the Pipeline 7/25/2017
HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway To Potential Regulatory Submission 7/25/2017
Q Therapeutics, Inc. Release: FDA Allows Q-Cells For First-In-Human Transverse Myelitis Trial 7/25/2017
Kadmon Announces Supplemental Interim Phase II Data Of KD025 In Chronic Graft-Versus-Host Disease 7/25/2017
FDA Grants Fast Track Designation To Flex Pharma (FLKS)’s FLX-787 For The Treatment Of Severe Muscle Cramps Associated With ALS 7/25/2017
Verastem (VSTM) Publishes Scientific Data Highlighting Potential Role Of FAK Inhibition In Pancreatic And Breast Cancer 7/25/2017
Onconova (ONTX) Announces Establishment Of Collaborative Research And Clinical Programs Evaluating Rigosertib In Pediatric “Rasopathies” 7/25/2017
10 Biotechs Tackling Senator John McCain's Form of Aggressive Brain Cancer 7/24/2017
Eiger Biopharma Completes Enrollment In Phase II LIMT HDV Study Of Pegylated Interferon Lambda In Hepatitis Delta Virus Infection 7/24/2017
Theratechnologies (TH.TO) Announces New Findings With The Investigational Antiretroviral Ibalizumab And With EGRIFTA (Tesamorelin For Injection) 7/24/2017
Data Put A Dent In Ironwood (IRWD)'s Expansion Plans 7/24/2017
DelMar Pharma Receives Approval From China's Human Genetic Resources Administration To Initiate Phase II Clinical Trial In Newly Diagnosed GBM 7/24/2017
Stealth Biotherapeutics Initiates Phase II/III Study of Elamipretide In Patients With Barth Syndrome 7/24/2017
Tocagen Receives EMA Priority Medicines (PRIME) Designation For Toca 511 In High Grade Glioma 7/24/2017
BlackThorn Therapeutics Enrolls First Patient In Phase IIa Study Of Lead Compound, BTRX-246040, In Major Depressive Disorder 7/24/2017
Napo Pharmaceuticals, Inc. Release: New Data Shows Dramatic Reduction In Chronic Diarrhea Episodes With Crofelemer (Mytesi) Treatment 7/24/2017
BioLight Life Sciences Reports Successful Results In Phase I/IIa Clinical Trial For Glaucoma Insert 7/24/2017
Reata Pharmaceuticals, Inc.’s Bardoxolone Methyl Demonstrated Improved Kidney Function In Patients With Alport Syndrome In Ongoing Phase II Portion Of Phase II/III Cardinal Study 7/24/2017
Genocea (GNCA) Reports Positive Top-Line 12-Month Phase IIb Data For GEN-003 In Genital Herpes 7/24/2017
Janssen Sciences Ireland UC Releases: Data Published In Lancet Shows High Efficacy At 96 Weeks For First Investigational Two-Drug, Long-Acting Injectable HIV Regimen 7/24/2017
Vertex (VRTX) Gains $8 Billion Overnight as Cystic Fibrosis Combo Drug Wows in Trials 7/21/2017
Kite Pharma (KITE) Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy 7/21/2017
Uncertainty Hits as Roche (RHHBY) is Dealt Multiple Clinical Trial Setbacks 7/21/2017
Ironwood (IRWD)'s Potential Blockbuster Drug Meets Main Goals in Mid-Stage Trial 7/21/2017
Amgen (AMGN) Release: FDA Accepts Biologics License Application For Aimovig (erenumab) 7/21/2017
FDA Accepts Biologics License Application For AMG 334 (Erenumab), An Important Regulatory Milestone For Novartis AG (NVS) 7/21/2017
Syros Pharma Publishes Foundational Data Supporting Ongoing Phase II Clinical Trial Of SY-1425 For Genomically Defined AML And MDS Patients 7/21/2017
Merck KGaA (MKGAF.PK) Release: EMA's CHMP Issues Positive Opinion For Avelumab For The Treatment Of Metastatic Merkel Cell Carcinoma 7/21/2017
BiondVax's Universal Flu Vaccine Meets All Endpoints in Phase IIb Study 7/20/2017
Trevena (TRVN) To Host 2017 Analyst Day And Announce Results Of ATHENA Open Label Safety Study Of OLINVO 7/20/2017
Intra-Cellular Therapies (ITCI) Presents At The 2017 International College Of Neuro-Psychopharmacology (CINP) Thematic Meeting On Treatment-Resistant Depression 7/20/2017
Another Alzheimer's Let-Down as FUJIFILM's Candidate Flunks Phase II Test 7/19/2017
Genentech (RHHBY) R&D Exec Reveals Alzheimer's is Still A Priority 7/19/2017
How Much Money Will These 5 Pharma Companies' Pipelines Generate in 5 Years 7/19/2017
Data From BioTime (BTX)’s Phase I/IIa Opregen Trial To Be Presented At The 2017 American Academy of Ophthalmology Annual Meeting 7/19/2017
Tiziana Life Sciences Plc Announces Initiation Of A Phase IIa Clinical Trial With Milciclib In Patients With Hepatocellular Carcinoma 7/19/2017
Imago Biosciences Doses First Patients In The Phase IIa Portion Of The Study Of IMG-7289 In Acute Myeloid Leukemia And Myelodysplastic Syndrome 7/19/2017
BriaCell Provides Clinical Update On Its Ongoing Phase I/IIa Clinical Study Of BriaVax In Advanced Breast Cancer 7/19/2017
Neurotrope (NTRP) Presents Phase II Data Assessing Bryostatin-1 In Moderate-To-Severe Alzheimer's Patients At AAIC 2017 7/19/2017
Caladrius Biosciences (CLBS) Announces That 50% Of Subjects Have Been Treated In The Phase II Clinical Trial Of CLBS03 For Type 1 Diabetes 7/19/2017
Evolus Announces FDA Acceptance For Review Of The Biologics License Application For DWP-450 Neuromodulator 7/19/2017
In Alzheimer's, The 'Juggernaut Is Changing Course,' Says TauRx Pharma Chief Exec 7/18/2017
Centrexion Provides Updates And Advancements For Pipeline Of Chronic Pain Treatments 7/18/2017
Aldeyra (ALDX) Announces Last Patient Dosed In Dry Eye Disease Phase IIa Clinical Trial 7/18/2017
Capricor (CAPR) Receives Rare Pediatric Disease Designation From FDA For CAP-1002 For Patients With Duchenne Muscular Dystrophy 7/18/2017
Can-Fite BioPharma (CFBI)’s Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting 7/17/2017
WAVE Life Sciences (WVE) Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 And PRECISION-HD2 In Patients With Huntington’s Disease 7/17/2017
Apexigen Announces First Patient Dosed In Phase Ib/II Clinical Trial Of APX005M In Combination With Opdivo (Nivolumab) In Advanced Solid Tumors 7/17/2017
Proclara Announces Pipeline Progress 7/17/2017
Asterias Biotherapeutics Completes Enrollment And Dosing Of SCiStar Study's AIS-A 20 Million Cell Cohort 7/17/2017
Cancer Prevention Pharma In Collaboration With The NCI And Vanderbilt University Medical Center Initiates Phase II Trial To Evaluate CPP-1X In Patients With High Risk Of Gastric Cancer 7/17/2017
Axsome (AXSM) Initiates Phase II/III Trial Of AXS-05 For Alzheimer’s Disease Agitation 7/17/2017
AXON Neuroscience's Tau Vaccine Has Completed Phase II Enrolment In Alzheimer's 7/17/2017
CymaBay Therapeutics Announces Positive Interim Results From Its Ongoing Low-Dose Phase II Study Of Seladelpar In Patients With Primary Biliary Cholangitis 7/17/2017
RedHill Biopharma (RDHL) Announces Last Patient Visit In BEKINDA Phase II Study For IBS-D 7/17/2017
No Relief For Investors As The FDA Keeps Partial Hold On Repros Therapeutics (RPRX)'s Proellex Program 7/17/2017
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II 7/14/2017
Innovation Pharma (Formerly known as Cellceutix) (CTIX) Phase II PoC Trial For Inflammatory Bowel Disease Achieves Induction Of Remission In A Majority Of Patients Treated With Brilacidin 7/14/2017
San Diego's Arena (ARNA) Soars as Phase II Hypertension Trial Data Wows 7/13/2017
Viamet Release: FDA Grants Fast Track Designation To VT-1598 For Treatment Of Valley Fever 7/13/2017
Initiation Of Clinical Trial Collaboration Evaluating Halozyme (HALO)'s PEGPH20 In Combination With Anti-PDL1 Immunotherapy 7/13/2017
Advaxis (ADXS) Lead Immunotherapy Candidate Continues To Build Recognition Among Industry Leaders 7/13/2017
New Experimental Data On Anti-Inflammatory Effects Of ABX464, Abivax (ABVX.PA)'s First-In-Class Drug Candidate To Achieve Functional Cure In HIV-Patients, Published In Nature Scientific Reports 7/13/2017
Actinium (ATNM.OB) To Host Webinar Focused On Actimab-A And Recent Developments Related To CD33 Targeted AML Therapies On July 13, 2017 At 8:00 Am ET 7/13/2017
Publication In Cell Demonstrates Moderna’s Zika Mrna Vaccine Prevents In Utero Transmission Of Zika Virus In Mice, Protects Against Zika-Related Congenital Damage 7/13/2017
CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma 7/13/2017
FDA Grants Orphan Drug Designation To Mallinckrodt (MNK) Development Product For Potential Treatment Of Duchenne Muscular Dystrophy 7/13/2017
FDA Grants Orphan Drug Designation To Allena Pharma’ Investigational Therapy For The Treatment Of Primary Hyperoxaluria 7/13/2017
Dimerix Limited Reports Positive Results From Phase IIa Trial Of DMX-200 In Chronic Kidney Disease 7/12/2017
Viking Therapeutics (VKTX) Completes Enrollment In Phase II Study Of VK5211 In Patients Recovering From Hip Fracture 7/12/2017
Neuraltus Pharmaceuticals, Inc. Announces Completion Of Enrollment In Confirmatory Phase II Study Of NP001 In ALS Patients With Systemic Inflammation 7/12/2017
Asterias Biotherapeutics Completes Enrollment And Dosing Of SCiStar Study's Ais-B 10 Million Cell Cohort 7/12/2017
Camurus And Braeburn Pharma Announce Topline Phase II Results For Long-Acting Buprenorphine In Opioid Dependent Patients With Chronic Pain 7/12/2017
QR Pharma Presents New Data On Posiphen In Down Syndrome At The Alzheimer's Disease International Conference (AAIC 2017 London) 7/12/2017
Vifor Pharma Announces Three Outcomes Trials In Heart Failure And Iron Deficiency 7/12/2017
Why Biogen (BIIB) Spinoff Bioverativ (BIVV)'s Anemia Drug Could Be A Blockbuster 7/11/2017
Savara Release: Positive Interim Results Of Aironite Phase II Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension 7/11/2017
BioMarin (BMRN)'s Investigational Gene Therapy For Hemophilia A At 6e13 Vg/Kg Dose Maintains Average Factor VIII Levels Within Normal Range For Over One Year 7/11/2017
ProMetic Life Sci (PFSCF.PK) Announces Positive Long Term Clinical Data On Ryplazym In Plasminogen Congenital Deficiency And Provides Regulatory Update 7/11/2017
Valerion Therapeutics, LLC Initiates VAL-1221 Dosing In Patients With Pompe Disease 7/11/2017
Oramed (ORMP) Announces End-Of-Phase II Meeting With FDA To Initiate Phase III Program 7/11/2017
Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA For Treatment Of Pemphigus Vulgaris 7/11/2017
Kadmon Announces Interim Phase II Data Of KD025 In Chronic Graft-Versus-Host Disease 7/11/2017



//-->